Arvelle Therapeutics Overview

  • Founded

  • 2019

Founded
  • Status

  • Acquired/​Merged

  • Employees

  • 60

Employees
  • Latest Deal Type

  • M&A

  • Latest Deal Amount

  • $960M

  • Investors

  • 1

Arvelle Therapeutics General Information

Description

Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorders. The company's therapies serve patients suffering from central nervous system disorders for debilitating neurological and neuromuscular diseases and are responsible for the development and commercialization of Cenobamate, enabling clinicians to provide proper medical care for focal seizures of patients.

Contact Information

Website
www.arvelletx.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Parent Company
Angelini Pharma
Primary Office
  • Zählerweg 6
  • 6301 Zug
  • Switzerland
+41 044 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arvelle Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 02-Feb-2021 $960M 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series A) 26-May-2020 00000 00000 Completed Generating Revenue
1. Corporate 01-Feb-2019 Completed Startup
To view Arvelle Therapeutics’s complete valuation and funding history, request access »

Arvelle Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorde
Drug Discovery
Zug, Switzerland
60 As of 2021
00000
0000 0000-00-00
000000&0 00000

000000

ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000 000000000
Kalamazoo, MI
00 As of 0000
0000
000000 - 000 0000

000000

dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
0000 000000000
Emeryville, CA
000 As of 0000
00000
0.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arvelle Therapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Metabolic Solutions Development Venture Capital-Backed Kalamazoo, MI 00 0000 000000 - 000 0000
0000000 Formerly VC-backed Emeryville, CA 000 00000 000000&0 00000
00000000 Corporation Julich, Germany 0 0000000000
00000 000000000000 Formerly VC-backed Burnaby, Canada 000 000.00 000000000 000.00
0000000 Venture Capital-Backed Palm Beach Gardens, FL 00 0000 000000 - 000 0000
You’re viewing 5 of 36 competitors. Get the full list »

Arvelle Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
llise Lombardo MD Co-Founder & Chief Medical Officer
Mark Altmeyer Co-Founder, President and Chief Executive Officer
Ilise Lombardo MD Co-Founder & Chief Medical Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Arvelle Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arvelle Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andera Partners PE/Buyout Minority 000 0000 000000 0
BRV Capital Management Growth/Expansion Minority 000 0000 000000 0
EQT Life Sciences Venture Capital Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
H.I.G. BioHealth Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Arvelle Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 00 20-Feb-2019 000000000 00000 Buildings and Property
To view Arvelle Therapeutics’s complete investments history, request access »

Ready to get started?

Request a free trial